Protective effect of low molecular fraction of MGN-3, a modified arabinoxylan from rice bran, on acute liver injury by inhibition of NF-κB and JNK/MAPK expression

  • Surina Zheng, Shunsuke Sugita, Shizuka Hirai, Yukari Egashira
  • 2012

D -Galactosamine (GalN) induces acute hepatitis in experimental animals; this hepatitis has been shown to be suppressed by oral or intraperitoneal administration of modified arabinoxylan from rice bran (MGN-3), and active low molecular fraction isolated from MGN-3 (LMW). We previously reported that this protective mechanism is mediated in part by downregulation of interleukin-18 (IL-18). The present study shows for the first time that nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK) and CD14 are involved in the suppressive action of LMW on GalN-induced hepatitis. Wistar rats (aged 4 weeks, SLC) were intraperitoneally treated with either MGN-3 or LMW. Then, rats were given GalN at 400 mg/kg at 1 h after the initial treatment. The serum activity of transaminases (ALT and AST) was significantly higher after GalN treatment; these changes were attenuated by MGN-3 and LMW. Furthermore, LMW abrogated inhibitor of κB kinase (IκB) degradation induced by GalN, and this was associated with the inhibition of NF-κB activa-tion. Moreover, phosphorylated stress-activated protein kinase/c-Jun N-terminal kinase (JNK) protein expression in the liver after GalN treatment was significantly higher, and LMW reduced this increase. We also found that GalN treatment induced TLR4 and CD14 mRNA expression, and LMW significantly inhibited CD14 mRNA expression. These results suggest that the suppressive effects of LMW on GalN-induced hepatitis are possibly related to inhibition of NF-κB, JNK phosphorylation and CD14 expression. 

We use cookies to improve your experience on our website. For more details see our cookie policy.

Like many other websites, we use cookies to provide enhanced functionality and track the usage of our websites with Google Analytics, and some of our third-party advertisers might use them to deliver adverts tailored to what they think you might be interested in.

What are cookies?

Cookies are small text files which can be sent to browser when you visit websites and saved to your device (computer or other device with Internet access, i.e. smartphone or tablet). Cookies are saved in the folder for files of your browser. Cookies usually contain the name of the website they come from and the date of origin. Upon your next visit the browser loads cookies again and sends these information back to the website which originally created cookies. Cookies we use do not harm your computer.

Using cookies

By using this website you give your consent to using cookies in compliance with your browser settings. If you visit our websites, acceptance of cookies is allowed in your browser, you do not change your browser settings and continue visiting our websites we consider it as accepting our conditions for using cookies.

Why are we using cookies?

Cookies are used to optimally create and constantly improve the quality of our services, adjust them to your interests and needs and improve their structure and contents. We do not use data obtained by using cookies to contact users by mail, e-mail or telephone.

How to change settings of cookies?

Majority of browsers have been originally set to automatically accept cookies. This settings can be changed by blocking cookies or by a notification in case cookies are to be sent to your device. Instructions for changing cookies are available in the option “Help” of every browser. If you use different devices to access websites (e.g. computer, smartphone, tablet), we recommend you to adjust every browser on each of them to your preferences regarding cookies.

Why to keep settings of cookies?

Using cookies and permitting cookies in your browser is your decision. However, in case you change settings of cookies, functionality of some of our websites can be limited and their user comfort reduced.